Table 4 Comparison of effective target areas and organ damage in radiotherapy for large tumours
From: 3D-printed brachytherapy in patients with cervical cancer: improving efficacy and safety outcomes
Variables | 3D radiotherapy | Freehand implant radiotherapy | t | P-value | |
|---|---|---|---|---|---|
(n = 101) | (n = 112) | ||||
Target area dose | |||||
CTV-D95 (Gy, \(\:\stackrel{-}{x}\)±s) | 53.03 ± 1.28 | 52.04 ± 1.82 | -4.604 | < 0.001*** | |
CTV-D98 (Gy, \(\:\stackrel{-}{x}\)±s) | 46.71 ± 2.35 | 45.41 ± 3.21 | -3.403 | < 0.001*** | |
CTV-D100 (Gy, \(\:\stackrel{-}{x}\)±s) | 33.41 ± 4.26 | 32.17 ± 4.64 | -2.034 | 0.043* | |
Dose-volume ratio | |||||
CTV-v100 (%, \(\:\stackrel{-}{x}\)±s) | 85.97 ± 5.26 | 90.72 ± 9.71 | 4.498 | < 0.001*** | |
CTV-v150 (%, \(\:\stackrel{-}{x}\)±s) | 61.72 ± 4.48 | 64.80 ± 6.10 | 4.237 | < 0.001*** | |
CTV-v200 (%, \(\:\stackrel{-}{x}\)±s) | 41.10 ± 5.80 | 44.57 ± 8.04 | 3.577 | < 0.001*** | |
Organ-damaging | |||||
Bladder irradiation dose D1CC (Gy, \(\:\stackrel{-}{x}\)±s) | 52.16 ± 9.92 | 61.28 ± 17.43 | 4.751 | < 0.001*** | |
Bladder irradiation dose D2CC (Gy, \(\:\stackrel{-}{x}\)±s) | 48.56 ± 8.36 | 55.42 ± 15.51 | 4.069 | < 0.001*** | |
Rectal irradiation dose D1CC (Gy, \(\:\stackrel{-}{x}\)±s) | 55.26 ± 59.51 | 59.42 ± 17.48 | 0.706 | 0.481 | |
Rectal irradiation dose D2CC (Gy, \(\:\stackrel{-}{x}\)±s) | 45.12 ± 9.76 | 52.75 ± 15.21 | 4.400 | < 0.001*** |